Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction

British Journal of Pharmacology

Volumn 141, Issue 1, 2004, Pages 9-14

  Frantz, Stefan ^a,b   Hu, Kai ^a   Widder, Julian ^a   Bayer, Barbara ^a   Witzel, Catharina Clara ^a   Schmidt, Isabel ^a   Galuppo, Paolo ^a   Strotmann, Jörg ^a   Ertl, Georg ^a   Bauersachs, Johann ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Collagen; Cytokine; Glitazone; Heart failure; Infarction

Indexed keywords

COLLAGEN; CYTOKINE; ENDOTHELIN 1; GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART LEFT VENTRICLE; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEART WEIGHT; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ANIMALS; AORTA; BLOOD GLUCOSE; BODY WEIGHT; CHRONIC DISEASE; COLLAGEN; CORONARY VESSELS; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ECHOCARDIOGRAPHY; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; INFLAMMATION MEDIATORS; INTUBATION, GASTROINTESTINAL; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCARDIUM; ORGAN SIZE; PHENYLEPHRINE; THIAZOLIDINEDIONES; TRIGLYCERIDES; VASOCONSTRICTION; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 10744225665     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705585     Document Type: Article

References (35)

1. ASAKAWA, M., TAKANO, H., NAGAI, T., UOZUMI, H., HASEGAWA, H., KUBOTA, N., SAITO, T., MASUDA, Y., KADOWAKI, T. & KOMURO, I. (2002). Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation, 105, 1240-1246.
2. BAUERSACHS, J., BOULOUMIE, A., FRACCAROLLO, D., HU, K., BUSSE, R. & ERTL, G. (1999). Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation, 100, 292-298.
3. BAUERSACHS, J., GALUPPO, P., FRACCAROLLO, D., CHRIST, M. & ERTL, G. (2001). Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation, 104, 982-985.
4. BISHOP-BAILEY, D. (2000). Peroxisome proliferator-activated receptors in the cardiovascular system. Br. J. Pharmacol., 129, 823-834.
5. BOZKURT, B., KRIBBS, S.B., CLUBB JR, F.J., MICHAEL, L.H., DIDENKO, V.V., HORNSBY, P.J., SETA, Y., ORAL, H., SPINALE, F.G. & MANN, D.L. (1998). Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation, 97, 1382-1391.
6. BRYANT, D., BECKER, L., RICHARDSON, J., SHELTON, J., FRANCO, F., PESHOCK, R., THOMPSON, M. & GIROIR, B. (1998). Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation, 97, 1375-1381.
7. BUCHANAN, T.A., Meehan, W.P., JENG, Y.Y., YANG, D., CHAN, T.M., NADLER, J.L., SCOTT, S., RUDE, R.K. & HSUEH, W.A. (1995). Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J. Clin. Invest., 96, 354-360.
8. DELEA, T., HAGIWARA, M., EDELSBERG, J. & OSTER, G. (2002). Exposure of glitazone antidiabetics and risk of heart failure among persons with type 2 diabetes: a retrospective population-based cohort analysis. JACC, 39, Abstract 858-3.
9. DELERIVE, P., MARTIN-NIZARD, F., CHINETTI, G., TROTTEIN, F., FRUCHART, J.C., NAJIB, J., DURIEZ, P. & STAELS, B. (1999). Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ. Res., 85, 394-402.
10. DUCHARME, FRANTZ, S., AIKAWA, M., RABKIN, E., LINDSEY, M., ROHDE, L.E., SCHOEN, F.J., KELLY, R.A., WERB, Z., LIBBY, P. & LEE, R.T. (2000). Targeted deletion of matrix metallaproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J. Clin. Invest., 106, 55-62.
11. FRACCAROLLO, D., HU, K., GALUPPO, P., GAUDRON, P. & ERTL, G. (1997). Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. Circulation, 96, 3963-3973.
12. FRANTZ, S., KELLY, R.A. & BOURCIER, T. (2001). Role of TLR-2 in the activation of nuclear factor-kappa B by oxidative stress in cardiac myocytes. J. Biol. Chem., 276, 5197-5203.
13. FRANTZ, S., KOBZIK, L., KIM, Y.D., FUKAZAWA, R., MEDZHITOV, R., LEE, R.T. & KELLY, R.A. (1999). Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J. Clin. Invest., 104, 271-280.
14. IKEDA, H., TAKETOMI, S., SUGIYAMA, Y., SHIMURA, Y., SOHDA, T., MEGURO, K. & FUJITA, T. (1990). Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittelforschung, 40, 156-162.
15. JIANG, C., TING, A.T. & SEED, B. (1998). PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature, 391, 82-86.
16. JUNQUEIRA, L.C., BIGNOLAS, G. & BRENTANI, R.R. (1979). Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem. J., 11, 447-455.
17. KAPLAN, F., AL-MAJALI, K. & BETTERIDGE, D.J. (2001). PPARS, insulin resistance and type 2 diabetes. J. Cardiovasc. Risk, 8, 211-217.
18. KUBOTA, T., MCTIERNAN, C.F., FRYE, C.S., SLAWSON, S.E., LEMSTER, B.H., KORETSKY, A.P., DEMETRIS, A.J. & FELDMAN, A.M. (1997). Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ. Res., 81, 627-635.
19. LYGATE, C.A., HULBERT, K., MONFARED, M., COLE, M., CLARKE, K. & NEUBAUER, S. (2003). The PPARg-activator rosiglitazone does not alter remodeling but increases mortalitzy in rats post-myocardial infarction. Cardiovasc. Res., 58, 632-637.
20. MARX, N. & HOMBACH, V. (2001). [Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells]. Z. Kardiol., 90, 470-477.
21. MARX, N., SCHONBECK, U., LAZAR, M.A., LIBBY, P. & PLUTZKY, J. (1998). Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res., 83, 1097-1103.
22. MCMURRAY, J.J., RAY, S.O., ABDULLAH, I., DARGIE, H.J. & MORTON, J.J. (1992). Plasma endothelin in chronic heart failure. Circulation, 85, 1374-1379.
23. ROHDE, L.E., DUCHARME, A., ARROYO, L.H., AIKAWA, M., SUKHOVA, G.H., LOPEZ-ANAYA, A., MITCHELL, K., LIBBY, P. & LEE, R.T. (1999). Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation, 99, 3063-3070.
24. SCHOONJANS, K. & AUWERX, J. (2000). Thiazolidinediones: an update. Lancet, 355, 1008-1010.
25. SHIOMI, T., TSUTSUI, H., HAYASHIDANI, S., SUEMATSU, N., IKEUCHI, M., WEN, J., ISHIBASHI, M., KUBOTA, T., EGASHIRA, K. & TAKESHITA, A. (2002). Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation, 106, 3126-3132.
26. SIDHU, J.S. & KASKI, J.C. (2001). Peroxisome proliferator activated receptor gamma: a potential therapeutic target in the management of ischaemic heart disease. Heart, 86, 255-258.
27. SIMONCIKOVA, P., WEIN, S., GASPERIKOVA, D., UKROPEC, J., CERTIK, M., KLIMES, I. & SEBOKOVA, E. (2002). Comparison of the extrapancreatic action of gamma-linolenic acid and n-3 PUFAs in the high fat diet-induced insulin resistance. Endocr. Regul., 36, 143-149.
28. TAKANO, H., NAGAI, T., ASAKAWA, M., TOYOZAKI, T., OKA, T., KOMURO, I., SAITO, T. & MASUDA, Y. (2000). Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ. Res., 87, 596-602.
29. TANG, W.H., FRANCIS, G.S., HOOGWERF, B.J. & YOUNG, J.B. (2003). Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J. Am. Coll. Cardiol., 41, 1394-1398.
30. TESTA, M., YEH, M., LEE, P., FANELLI, R., LOPERFIDO, F., BERMAN, J.W. & LEJEMTEL, T.H. (1996). Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J. Am. Coll. Cardiol. 28, 964-971.
31. TORRE-AMIONE, G., KAPADIA, S., BENEDICT, C., ORAL, H., YOUNG, J.B. & MANN, D.L. (1996). Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J. Am. Coll. Cardiol., 27, 1201-1206.
32. TSUJI, T., MIZUSHIGE, K., NOMA, T., MURAKAMI, K., OHMORI, K., MIYATAKE, A. & KOHNO, M. (2001). Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. J. Cardiovasc. Pharmacol., 38, 868-874.
33. WAYMAN, N.S., HATTORI, Y., MCDONALD, M.C., MOTA-FILlPE, H., CUZZOCREA, S., PISANO, B., CHATTERJEE, P.K. & THIEMERMANN. C. (2002). Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial mfarct size. FASEB J., 16, 1027-1040.
34. YAMAMOTO, K., OHKI, R., LEE, R.T., IKEDA, U. & SHIMADA, K. (2001). Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation, 104, 1670-1675.
35. YUE, T.-L., CHEN, J., BAO, W., NARAYANAN, P., BRIL, A., JIANG, W., LYSKO, P., GU, J.-L., BOYCE, R., ZIMMERMAN, D., HART, T., BUCKINGHAM, R. & OHLSTEIN, E. (2001). In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-agonist rosiglitazone. Circulation, 104, 2588-2594.